Search

Your search keyword '"Russo S"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Russo S" Remove constraint Author: "Russo S" Journal annals of oncology Remove constraint Journal: annals of oncology
38 results on '"Russo S"'

Search Results

1. Differences among young adults, adults and elderly chronic myeloid leukemia patients

2. 226P Exploring the impact of first-line therapies on the metastatic behavior of luminal-like metastatic breast cancer (mBC)

3. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort

4. 416P Prognostic impact of liquid biopsy (LB) biomarkers at relapse on second-line (2L) treatment (Tx) after progression to endocrine therapy (ET) in metastatic breast cancer (mBC): Ancillary analysis of the MAGNETIC.1 study

5. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

8. 307P Overall survival in metastatic breast cancer patients according to different follow up strategies for early breast cancer

9. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes

10. 252P Does the introduction of CDK4/6 inhibitors (CDKi) in first-line treatment of metastatic breast cancer (MBC) increase medical oncology workload?

11. LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial

12. 295P Clinical characterization and outcome of a HER2-low metastatic breast cancer (mBC) cohort receiving first-line treatment (1L) with ET +/- CDK 4/6 inhibitor (CDKi)

13. Differences among young adults, adults and elderly chronic myeloid leukemia patients

14. 415P Patterns of time-to-progression intervals across clinical and liquid biopsy (LB) features in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with first-line endocrine therapy (ET)

15. LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

17. 82P Novel analysis of F. nucleatum subspecies in human CRC tissue and engineering of therapeutic F. nucleatum phage

18. LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial

20. Clinical decision making and multidisciplinary team meetings (MDMs) in early breast cancer. Is the agreement between planned and applied therapeutic program?

21. A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients

22. Monitoring metastatic breast cancer (M-MBC) during treatment: a GIM (Gruppo Italiano Mammella) survey

23. Final results from CAMEO-PRO study: complementary and alternative medicine in oncology. physicians inform oncological patients

24. Strategy of monitoring metastatic breast cancer (M-MBC) in clinical practice: more or less intensive?

25. Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study

27. Treatment strategies in patients with Metastatic Breast Cancer: real-world practice in the United Kingdom (UK) and Italy

28. Last-line treatment of luminal metastatic breast cancer: which factors influence the therapeutic choice?

30. Luminal-like metastatic breast cancer: which is the room of endocrine maintenance therapy after first line chemotherapy?

31. Risk of unplanned presentations and hospital admission of metastatic breast cancer outpatients

32. Last-line treatment of advanced breast cancer: outcome measures and prognostic factors

33. Unplanned hospital admission of early breast cancer outpatients treated with adjuvant chemotherapy

36. 301P - Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Old drugs, new opportunities Preliminary results of the VICTOR-6 study

Catalog

Books, media, physical & digital resources